Welcome to our dedicated page for EFFECTOR THERAPUTCS news (Ticker: EFTR), a resource for investors and traders seeking the latest updates and insights on EFFECTOR THERAPUTCS stock.
eFFECTOR Therapeutics, Inc., headquartered in San Diego, is a cutting-edge biotechnology company that focuses on developing a novel class of oncology drugs known as selective translation regulator inhibitors (STRIs). The company's mission is to advance cancer treatment by targeting key molecular mechanisms that drive the disease.
eFFECTOR's flagship product, zotatifin, is currently under Phase 1/2 clinical trials for ER+/HER2- metastatic breast cancer. Recently, zotatifin received Fast Track designation from the U.S. FDA in combination with fulvestrant and abemaciclib, underscoring its potential in treating advanced or metastatic breast cancer. In these trials, zotatifin showed promising results with a 26% partial response rate in heavily pretreated patients.
Another key product in eFFECTOR's pipeline is tomivosertib, an MNK inhibitor being evaluated in a Phase 2b trial for metastatic non-small cell lung cancer (NSCLC). The company's research extends to other biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC.
eFFECTOR is also collaborating globally with Pfizer to develop inhibitors targeting eIF4E, further enhancing its research capabilities and clinical development. This partnership aims to streamline the translation of groundbreaking findings into viable treatments for cancer patients.
Financially, eFFECTOR continues to strengthen its position through strategic offerings, raising approximately $15 million in recent direct offerings. This capital helps advance their research projects and maintain a robust developmental pipeline.
Additionally, eFFECTOR announced a reverse stock split aimed at regaining compliance with Nasdaq's minimum bid price requirements, effective January 12, 2024. This move is intended to better position the company within the stock market, ensuring long-term growth and stability.
Stay updated with eFFECTOR's latest developments as they continue to innovate in the field of oncology, pushing the boundaries of cancer treatment.
eFFECTOR Therapeutics (NASDAQ: EFTR) announced participation in the 2022 BIO CEO & Investor Conference. CEO Steve Worland will present the company’s clinical pipeline on February 14 at 9:45 am ET. CFO Mike Byrnes will join a panel discussion on SPACs on February 16 at 3:00 pm ET. eFFECTOR focuses on developing selective translation regulator inhibitors (STRIs) aimed at cancer treatment, specifically targeting the eIF4F complex. Their lead candidate, tomivosertib, is in a Phase 2b trial for metastatic non-small cell lung cancer.
eFFECTOR Therapeutics has updated its development strategy for tomivosertib, adding a new cohort in the KICKSTART trial targeting patients with PD-L1 ≥1%, expanding the potential U.S. market to $5 billion. The company also initiated two new cohorts for zotatifin in breast cancer and KRAS G12C-mutant NSCLC. Additionally, an investment agreement with Lincoln Park Capital allows for up to $50 million funding. Topline data from the KICKSTART trial is expected in 2023.
eFFECTOR Therapeutics recently published significant findings on the anti-tumor effects of zotatifin, a selective inhibitor targeting the eukaryotic translation initiation factor 4A (eIF4A), in the peer-reviewed journal Frontiers in Oncology. The research demonstrates zotatifin's ability to downregulate receptor tyrosine kinases (RTKs) commonly overexpressed in various cancers. Additionally, combining zotatifin with PI3K and AKT inhibitors showed enhanced anti-tumor activity in preclinical models. The company is currently advancing zotatifin through Phase 2a expansion cohorts in biomarker-positive solid tumors.
eFFECTOR Therapeutics (NASDAQ: EFTR) announced that CEO Steve Worland will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 6 at 3:20 p.m. ET. The event will be available via a live webcast on the Company’s Investor page, with a replay accessible for 30 days post-event. eFFECTOR is focused on developing selective translation regulator inhibitors (STRIs) for cancer treatment, including tomivosertib and zotatifin, which are currently undergoing clinical trials for various cancers and COVID-19.
eFFECTOR Therapeutics (NASDAQ: EFTR) reported its Q3 2021 financial results and provided a corporate update. Significant milestones include ongoing patient enrollment in the Phase 2b KICKSTART study for tomivosertib in combination with pembrolizumab, and the selection of the recommended Phase 2 dose for zotatifin. The company had a cash position of $54.8 million and achieved a net income of $8.9 million. R&D expenses decreased to $5 million, while G&A expenses rose to $4.1 million, reflecting increased public company related costs.
eFFECTOR Therapeutics (NASDAQ: EFTR) announced the appointment of Barbara Klencke, M.D., a seasoned oncology expert, to its board of directors. Dr. Klencke brings over 28 years of experience, enhancing eFFECTOR's clinical development capabilities. Concurrently, Larry Lasky, Ph.D., has resigned from the board. Dr. Klencke's expertise is expected to drive advancements in the clinical pipeline of selective translation regulator inhibitors (STRIs) aimed at cancer treatment. eFFECTOR focuses on innovative oncology drugs and is evaluating lead candidate tomivosertib in ongoing clinical trials.
eFFECTOR Therapeutics (NASDAQ: EFTR) announced its participation in upcoming investor conferences, including a presentation at the Credit Suisse 30th Annual Virtual Healthcare Conference on November 8 at 12:10 PM EST and a Fireside Chat at the Stifel 2021 Virtual Healthcare Conference on November 17 at 3:20 PM EST. Webcasts of these events will be available on the company's website for 30 days post-event. eFFECTOR focuses on developing selective translation regulator inhibitors for cancer treatment, with its lead candidate, tomivosertib, in a Phase 2b trial for metastatic non-small cell lung cancer.
eFFECTOR Therapeutics (NASDAQ: EFTR) announced promising findings for zotatifin in treating triple-negative breast cancer (TNBC) at the AACR-NCI-EORTC Conference. The preclinical study showed zotatifin's ability to control tumor growth and enhance immune response when combined with traditional chemotherapy agents. Notably, it significantly increased survival rates compared to isolated treatments. By impeding eIF4A, zotatifin not only inhibited tumor proliferation but also positively altered the tumor microenvironment, indicating potential benefits in challenging cancer types.
eFFECTOR Therapeutics (NASDAQ: EFTR) announced that research supported by them from Baylor College of Medicine was accepted for poster presentation at the upcoming 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
The study titled, “The RNA helicase EIF4A is a therapeutic vulnerability in triple-negative breast cancer,” will be available from October 7 to October 10, 2021. The event showcases innovations in drug development and molecular biology.
eFFECTOR Therapeutics (NASDAQ: EFTR) will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 2:40 p.m. ET. The company will also conduct investor meetings during the conference. A live webcast of the chat will be accessible on their website, with a replay available for 30 days. eFFECTOR focuses on developing selective translation regulator inhibitors (STRIs) for cancer treatment, with its lead candidate, tomivosertib, currently in a Phase 2b trial for metastatic non-small cell lung cancer.
FAQ
What is the current stock price of EFFECTOR THERAPUTCS (EFTR)?
What is the market cap of EFFECTOR THERAPUTCS (EFTR)?
What is eFFECTOR Therapeutics' primary focus?
What recent achievement did eFFECTOR announce?
What products are in eFFECTOR's pipeline?
How is eFFECTOR collaborating with other companies?
What are the financial highlights of eFFECTOR?
What is the significance of the recent reverse stock split?
What types of cancer are eFFECTOR's products targeting?
What is the potential benefit of zotatifin's Fast Track designation?
How is eFFECTOR funded for its developments?
What are the recent clinical trial results for zotatifin?
